Management of Cirrhosis with Thrombocytopenia

Understanding Thrombocytopenia in Cirrhosis

The American Association for the Study of Liver Diseases recommends that thrombocytopenia in patients with cirrhosis should not be routinely corrected unless there is active bleeding or a high-risk procedure is planned, as the rebalanced hemostatic system in cirrhosis often maintains adequate function despite low platelet counts 1, 2
Bone marrow suppression from underlying disease, such as alcohol or viral hepatitis, is a mechanism contributing to thrombocytopenia in cirrhosis 3
Immunological processes affecting platelet destruction also play a role in the development of thrombocytopenia in cirrhosis 3
Increased levels of von Willebrand factor and decreased ADAMTS-13 levels counteract thrombocytopenia in patients with cirrhosis, contributing to a rebalanced hemostatic system 3
Reduced coagulation factors are balanced by decreased production of natural anticoagulants, such as protein C, protein S, and antithrombin, in patients with cirrhosis 3

The European Association for the Study of the Liver states that thrombocytopenia alone is not a reliable predictor of procedural bleeding risk in patients with liver disease 2, 3
Traditional coagulation tests, such as INR and APTT, do not accurately predict bleeding risk in cirrhosis, according to the American Association for the Study of Liver Diseases 2, 4
Laboratory evaluation of hemostasis is not indicated for low-risk procedures, as recommended by the European Association for the Study of the Liver 4

For low-risk procedures, the American Association for the Study of Liver Diseases recommends that no correction of thrombocytopenia is needed, regardless of platelet count 2, 4
For high-risk procedures, an individualized approach is recommended for patients with severe thrombocytopenia, as suggested by the European Association for the Study of the Liver 2, 5
Correction of prolonged INR with fresh frozen plasma is not recommended to decrease procedure-related bleeding, according to the American Association for the Study of Liver Diseases 4

The American Association for the Study of Liver Diseases recommends the use of thrombopoietin receptor agonists, such as avatrombopag and lusutrombopag, for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo procedures 2
These agents require a 2-8 day course before the scheduled procedure, as recommended by the European Association for the Study of the Liver 2
Platelet transfusions should be reserved for active bleeding or as rescue therapy, according to the American Association for the Study of Liver Diseases 1, 2

Anticoagulation should not be withheld in patients with moderate thrombocytopenia secondary to advanced liver disease, as recommended by the International Society on Thrombosis and Haemostasis 5
For platelet counts <50×10^9/L, decisions should be made case-by-case based on the site and extent of thrombosis, risk of thrombus extension, and presence of active bleeding or additional bleeding risk factors, according to the International Society on Thrombosis and Haemostasis 5, 6

For Child-Pugh A or B cirrhosis, either direct oral anticoagulants or low-molecular-weight heparin with or without vitamin K antagonists can be used, as recommended by the International Society on Thrombosis and Haemostasis 5, 6
For Child-Pugh C cirrhosis, low-molecular-weight heparin alone or as a bridge to vitamin K antagonists in patients with normal baseline INR is recommended, according to the International Society on Thrombosis and Haemostasis 5, 6

Management of bleeding related to portal hypertension should focus on portal hypertension-lowering measures rather than correction of thrombocytopenia, as recommended by the European Association for the Study of the Liver 7, 8
Correction of hemostatic abnormalities should be considered only if portal hypertension-lowering drugs fail to control bleeding, according to the European Association for the Study of the Liver 7

Standard anticoagulation prophylaxis is suggested for hospitalized cirrhotic patients who otherwise meet criteria for VTE prophylaxis, despite thrombocytopenia, as recommended by the American Gastroenterological Association 9

Assuming that abnormal coagulation tests predict bleeding risk in cirrhosis, as warned against by the American Association for the Study of Liver Diseases 1, 2
Routine correction of thrombocytopenia before procedures without evidence of benefit, as cautioned against by the European Association for the Study of the Liver 2, 4
Using platelet transfusions as first-line therapy, which may increase portal pressure, as warned against by the American Association for the Study of Liver Diseases 1
Withholding necessary anticoagulation based solely on platelet count, as cautioned against by the International Society on Thrombosis and Haemostasis 5, 6